La chaîne d'options affiche les données clés des options sur actions de Nutex Health à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour Nutex Health..

Nutex Health (NASDAQ:NUTX) Stock, Chaîne d'Options

Nutex Health

Nutex Health Inc is healthcare services and operations company with 20 hospital facilities in eight states (hospital division), and a primary care-centric, risk-bearing population health management division. The hospital division implements and operates healthcare models, including micro-hospitals, specialty hospitals and hospital outpatient departments (HOPDs). The population health management division owns and operates provider networks such as independent physician associations (IPAs) and offers a cloud-based proprietary technology platform to IPAs that aggregates clinical and claims data across multiple settings, information systems and sources to create a holistic view of patients and providers.

National Research (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRC#NASDAQ">NRC</a>) reported quarterly earnings of $0.28 per share. This is a 7.69 percent increase over earnings of $0.26 per share from the same period last year. The company reported $34.038 million in sales this quarter. This is a 2.81 percent decrease over sales of $35.021 million the same period last year.

Earnings

News

CORRECTION: National Research Q2 Adj. EPS $0.28 Up From $0.26 YoY, Sales $34.038M Down From $35.021M YoY

UBS analyst Brian Meredith maintains Goosehead Insurance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GSHD#NASDAQ">GSHD</a>) with a Buy and lowers the price target from $140 to $136.

Price Target

Analyst Ratings

GSHD

UBS Maintains Buy on Goosehead Insurance, Lowers Price Target to $136

Celestica Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLS#NYSE">CLS</a>) reported financial results for the second quarter on Monday after the bell. Here&#8217;s a rundown of the <a href="https://www.benzinga.com/pressreleases/25/07/g46673477/celestica-announces-second-quarter-2025-financial-results">supply chain solutions company&#8217;s report</a>.
<ul class="wp-block-list">
<li>Q2 Revenue:&nbsp;$2.89 billion, versus&nbsp;<a href="http://benzinga.com/quote/CLS/earnings" target="_blank" rel="noreferrer noopener">estimates</a>&nbsp;of $2.65 billion</li>
<li>Q2 Adjusted EPS: $1.39, versus estimates of $1.22</li>
</ul>
Find out how CLS stock is currently doing: <a href="https://www.benzinga.com/quote/CLS" target="_blank" rel="noreferrer noopener">See the chart here.</a>
Total revenue was up 21% on a year-over-year basis, bolstered by &#8220;strong&#8221; adjusted operating margin.
Celestica said it repurchased 600,000 shares of its common stock for $40 million in the quarter. The company ended the period with $313.8 million in cash and cash equivalents.
&#8220;With our strong first half results, and a strengthening demand&nbsp;outlook&nbsp;from our CCS customers, we are increasing our full-year 2025&nbsp;outlook,&#8221; said Rob Mionis, president and CEO of Celestica.
Guidance:&nbsp;Celestica guided for third-quarter revenue of $2.88 billion to $3.13 billion versus estimates of $2.77 billion. The company expects third-quarter adjusted earnings to be in the range of $1.37 to $1.53 per share, versus&nbsp;<a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>&nbsp;estimates of $1.28 per share.
Celestica also raised its full-year 2025 outlook. The company now expects 2025 revenue of $11.55 billion, up from prior guidance of $10.85 billion. Celestica sees adjusted earnings of $5.50 per share, up from prior guidance of $5 per share. According to <a href="http://pro.benzinga.com">Benzinga Pro</a> estimates, analysts are looking for revenue of $10.95 billion and earnings of $5.02 per share. 
CLS Price Action: <a href="http://benzinga.com/quote/cls" target="_blank" rel="noreferrer noopener">Celestica shares</a> were up 10.17% in after-hours Monday, trading at $191 at the time of publication, according to <a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/earnings/25/07/46674619/cadence-design-systems-beats-q2-earnings-estimates-raises-fy25-outlook-citing-broad-based-strength-ai-tailwinds">Cadence Design Systems Beats Q2 Earnings Estimates, Raises FY25 Outlook Citing &#8216;Broad-Based Strength,&#8217; AI Tailwinds</a></li>
</ul>
Photo: <a href="https://www.shutterstock.com/g/JHVEPhoto">JHVEPhoto</a>/Shutterstock.com

Guidance

Global

After-Hours Center

Movers

Celestica Stock Surges On Q2 Earnings Beat, Company Raises 2025 Outlook On 'Strengthening' Demand

UBS analyst Ashwani Verma maintains Immunovant (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMVT#NASDAQ">IMVT</a>) with a Neutral and raises the price target from $17 to $18.

IMVT

UBS Maintains Neutral on Immunovant, Raises Price Target to $18

UBS analyst Damian Karas maintains A.O. Smith (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AOS#NYSE">AOS</a>) with a Neutral and raises the price target from $74 to $76.

UBS Maintains Neutral on A.O. Smith, Raises Price Target to $76

UBS analyst Timothy Arcuri maintains Advanced Micro Devices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) with a Buy and raises the price target from $150 to $210.

UBS Maintains Buy on Advanced Micro Devices, Raises Price Target to $210

Sarepta Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) shares were halted in extended trading Monday after the U.S. Food and Drug Administration (FDA) recommended the removal of a <a href="https://www.benzinga.com/pressreleases/25/07/b46675040/fda-informs-sarepta-that-it-recommends-that-sarepta-remove-its-pause-and-resume-shipments-of-elevi">voluntary hold for Elevidys</a>.
What Happened: The FDA announced late Monday that it recommended lifting the voluntary hold on Sarepta Therapeutics&#8217; gene therapy for Duchenne Muscular Dystrophy.&nbsp;The company said in a statement that it was notified by the FDA on Monday and plans to resume shipping Elevidys&nbsp;to sites of care for treatment of ambulatory patients with Duchenne &#8220;imminently.&#8220;
The news comes after the FDA announced on Friday that it was investigating the <a href="https://www.benzinga.com/news/fda/25/07/46657622/fda-probes-death-of-8-year-old-who-received-sareptas-elevidys">death of an 8-year-old</a> in Brazil who had received Elevidys. Sarepta said the FDA determined the death was unlikely to be related to treatment with Elevidys, which is the only approved gene therapy for Duchenne.
&#8220;Last week, at the suggestion of FDA, Sarepta made the difficult decision to pause shipments of ELEVIDYS to provide the FDA with an opportunity to complete a review of available safety information. We are very pleased that FDA chose to rapidly and comprehensively complete that review and to recommend that we remove our voluntary pause and resume shipment of ELEVIDYS for ambulatory patients,&#8221; said Doug Ingram, CEO of Sarepta Therapeutics.
Sarepta said Elevidys treatment for&nbsp;non-ambulatory patients remains on pause pending the outcome of upcoming discussions with the FDA regarding the company&#8217;s approach to risk-mitigation. 
SRPT Price Action: <a href="http://benzinga.com/quote/SRPT">Sarepta shares</a> closed Monday up 16.18% at $13.86. The stock was briefly halted after-hours. Shares were up 50.57% at $20.87 at the time of publication, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/earnings/25/07/46665188/revvity-slashes-outlook-as-china-policy-deals-diagnostics-blow">Revvity Slashes Outlook As China Policy Deals Diagnostics Blow</a></li>
</ul>
Photo: Shutterstock.

Biotech

Health Care

SRPT

Sarepta Therapeutics Stock Soars After FDA Removes Hold On Elevidys For Some Patients

UBS analyst Timothy Arcuri maintains GLOBALFOUNDRIES (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GFS#NASDAQ">GFS</a>) with a Neutral and raises the price target from $37 to $43.

UBS Maintains Neutral on GLOBALFOUNDRIES, Raises Price Target to $43

UBS analyst Stephen Ju maintains Tripadvisor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRIP#NASDAQ">TRIP</a>) with a Neutral and raises the price target from $16 to $18.

TRIP

UBS Maintains Neutral on Tripadvisor, Raises Price Target to $18

UBS analyst Stephen Ju maintains Expedia Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXPE#NASDAQ">EXPE</a>) with a Neutral and raises the price target from $166 to $182.

EXPE

UBS Maintains Neutral on Expedia Group, Raises Price Target to $182

H2O America (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTO#NASDAQ">HTO</a>) reported quarterly earnings of $0.75 per share which beat the analyst consensus estimate of $0.66 by 14.5 percent. This is a 13.64 percent increase over earnings of $0.66 per share from the same period last year. The company reported quarterly sales of $198.255 million which beat the analyst consensus estimate of $186.643 million by 6.22 percent. This is a 12.53 percent increase over sales of $176.174 million the same period last year.

Earnings Beats

H2O America Q2 Adj. EPS $0.75 Beats $0.66 Estimate, Sales $198.255M Beat $186.643M Estimate

UBS analyst Stephen Ju maintains Booking Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKNG#NASDAQ">BKNG</a>) with a Buy and raises the price target from $5750 to $6300.

BKNG

UBS Maintains Buy on Booking Holdings, Raises Price Target to $6300

The U.S. national debt goes up every minute and with the passage of the One Big Beautiful Bill under President Donald Trump <a href="https://www.benzinga.com/news/politics/25/07/46235830/trump-wants-rate-cuts-will-big-beautiful-bill-help-answer-big-fat-no">could rise even further</a> in the coming years.
American residents are not required to help pay down the debt, but the government does allow that option.
What Happened: A quick look at the <a href="https://www.benzinga.com/topic/national-debt">U.S. National Debt </a>shows a total of $37.16 trillion and counting on Monday.
This <a href="https://www.usdebtclock.org/">translates </a>to around $108,348 per citizen.
Economists believe the national debt can grow under the Big Beautiful Bill by more than $3 trillion.
While costs could go up for consumers, they aren't required to help pay off the national debt.
For those willing to pay off the debt and provide gifts to "reduce the public debt," the government has a <a href="https://www.pay.gov/public/form/start/23779454">website </a>that does just that.
The national government accepts bank accounts and debit or credit cards for payments. Users with a Venmo or PayPal account, which are both owned by PayPal Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYPL#NASDAQ">PYPL</a>), can use those accounts to help pay off the national debt.
Read Also: <a href="https://www.benzinga.com/markets/macro-economic-events/25/07/46213919/elon-musk-is-100-correct-says-balaji-srinivasan-america-is-broke-and-there-is-no-fix-but-is-it-a-win-win-for-bitcoin">Elon Musk Is 100% Correct, Says Balaji Srinivasan: America Is &#8216;Broke&#8217; And There Is &#8216;No Fix&#8217; But Is It A Win-Win For Bitcoin?</a>
Why It's Important: A <a href="https://x.com/jackcorrbit/status/1948139892720234888">tweet </a>from NPR's Jack Corbett went viral recently with more than six million views on social media platform X. In the post, Corbett said, "You can Venmo the United States to help pay off the national debt."
As <a href="https://www.theverge.com/news/713980/us-national-debt-treasury-department-reduce-pay-venmo">reported </a>by The Verge, the efforts of the government have raised more than a few dollars, too. Since September 1998, <a href="https://fiscaldata.treasury.gov/datasets/gift-contributions-reduce-debt-held-by-public/gift-contributions-to-reduce-the-public-debt">over </a>$67 million has been donated as gifts to help reduce the public national debt.
For many, the tweet was likely out of touch, as most consumers are struggling to pay off their own debt and put money into savings with higher costs of living realized in recent years amid inflation and higher prices at the grocery store.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/financing/25/07/46215083/how-trumps-big-beautiful-bill-impacts-snap-medicaid-taxes-and-student-loans">How Trump&#8217;s &#8216;Big Beautiful Bill&#8217; Impacts SNAP, Medicaid, Taxes, Student Loans</a></li>
</ul>
Photo: viewimage via Shutterstock

Government

Education

PYPL

Want To Help Pay Off $37 Trillion National Debt? Government Accepts Venmo, PayPal

Starcore Intl Mines (TSX:<a class="ticker" href="https://www.benzinga.com/stock/SAM#TSX">SAM</a>) reported quarterly earnings of $0.02 per share. This is a 66.67 percent decrease over earnings of $0.06 per share from the same period last year. The company reported $9.368 million in sales this quarter. This is a 0.35 percent increase over sales of $9.335 million the same period last year.

TSX:SAM

Starcore Intl Mines Q4 GAAP EPS $0.02 Down From $0.06 YoY, Sales $9.368M Up From $9.335M YoY

UBS analyst Stephen Ju maintains Airbnb (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABNB#NASDAQ">ABNB</a>) with a Neutral and raises the price target from $137 to $156.

ABNB

UBS Maintains Neutral on Airbnb, Raises Price Target to $156

UBS analyst Joseph Spak maintains Lear (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEA#NYSE">LEA</a>) with a Neutral and lowers the price target from $116 to $109.

UBS Maintains Neutral on Lear, Lowers Price Target to $109

UBS analyst Joseph Spak maintains Gentex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNTX#NASDAQ">GNTX</a>) with a Neutral and raises the price target from $23 to $28.

GNTX

UBS Maintains Neutral on Gentex, Raises Price Target to $28

UBS analyst Gavin Parsons maintains Hexcel (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HXL#NYSE">HXL</a>) with a Neutral and raises the price target from $60 to $65.

UBS Maintains Neutral on Hexcel, Raises Price Target to $65

During the last three months, 4 analysts shared their evaluations of Savers Value Village (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SVV#NYSE">SVV</a>), revealing diverse outlooks from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Savers Value Village, revealing an average target of $11.75, a high estimate of $15.00, and a low estimate of $10.00. This current average has increased by 25.94% from the previous average price target of $9.33. 
<img src="https://www.benzinga.com/files/images/story/2025/1753740082_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
A comprehensive examination of how financial experts perceive Savers Value Village is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Matthew Boss</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$11.00</td>
<td>$9.00</td>
</tr>
<tr>
<td>Owen Rickert</td>
<td>Northland Capital Markets</td>
<td>Announces</td>
<td>Outperform</td>
<td>$15.00</td>
<td>-</td>
</tr>
<tr>
<td>Brooke Roach</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Neutral</td>
<td>$10.00</td>
<td>$9.00</td>
</tr>
<tr>
<td>Peter Keith</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$11.00</td>
<td>$10.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Savers Value Village. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Savers Value Village compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Savers Value Village's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Savers Value Village's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/SVV/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Savers Value Village analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>About Savers Value Village</h2>
Savers Value Village Inc is a for-profit thrift operator in the United States and Canada. It purchases second hand textiles (i.e., clothing, bedding, and bath items), shoes, accessories, housewares, books, and other goods from its non-profit partners (NPPs), either directly from them or via on-site donations (OSDs) at Community Donation Centers at its stores. The company then processes, selects, prices, merchandise, and sells these items in its stores.
<h3>Savers Value Village: Delving into Financials</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: Savers Value Village displayed positive results in 3M. As of 31 March, 2025, the company achieved a solid revenue growth rate of approximately 4.51%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Consumer Discretionary sector.
Net Margin: Savers Value Village's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of -1.28%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Savers Value Village's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -1.13%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Savers Value Village's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -0.25%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 3.11, caution is advised due to increased financial risk.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Deep Dive Into Savers Value Village Stock: Analyst Perspectives (4 Ratings)

6 analysts have expressed a variety of opinions on Kinsale Cap Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KNSL#NYSE">KNSL</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $511.33, a high estimate of $560.00, and a low estimate of $460.00. Surpassing the previous average price target of $475.40, the current average has increased by 7.56%.
<img src="https://www.benzinga.com/files/images/story/2025/1753740073_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
A comprehensive examination of how financial experts perceive Kinsale Cap Gr is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Casey Alexander</td>
<td>Compass Point</td>
<td>Raises</td>
<td>Neutral</td>
<td>$490.00</td>
<td>$432.00</td>
</tr>
<tr>
<td>Mark Hughes</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$560.00</td>
<td>$500.00</td>
</tr>
<tr>
<td>Pablo Singzon</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$460.00</td>
<td>$440.00</td>
</tr>
<tr>
<td>Joseph Tumillo</td>
<td>B of A Securities</td>
<td>Announces</td>
<td>Buy</td>
<td>$543.00</td>
<td>-</td>
</tr>
<tr>
<td>Bob Huang</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$525.00</td>
<td>$490.00</td>
</tr>
<tr>
<td>Bob Huang</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$490.00</td>
<td>$515.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Kinsale Cap Gr. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Kinsale Cap Gr compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Kinsale Cap Gr's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
For valuable insights into Kinsale Cap Gr's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/KNSL/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Kinsale Cap Gr analyst ratings.</a>
<h2>Discovering Kinsale Cap Gr: A Closer Look</h2>
Kinsale Capital Group Inc is an insurance holding company. The company is engaged in offering property, casualty, and specialty insurance products. It offers specialty insurance products for allied health, healthcare, life sciences, professional, and a public entity. The company operates in only one reportable segment which is the Excess and Surplus Lines Insurance segment, which includes commercial excess and surplus lines liability and property insurance products through its underwriting divisions. The company generates revenues in the form of premiums and investment income.
<h3>Breaking Down Kinsale Cap Gr's Financial Performance</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Positive Revenue Trend: Examining Kinsale Cap Gr's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 22.17% as of 30 June, 2025, showcasing a substantial increase in top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Financials sector.
Net Margin: Kinsale Cap Gr's net margin excels beyond industry benchmarks, reaching 28.55%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 8.11%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Kinsale Cap Gr's ROA stands out, surpassing industry averages. With an impressive ROA of 2.49%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Kinsale Cap Gr's debt-to-equity ratio is below the industry average at 0.11, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>How Are Analyst Ratings Determined?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

KNSL

Forecasting The Future: 6 Analyst Projections For Kinsale Cap Gr

Press Releases

Nutex Health Responds to Short Seller Report

Small Cap

Securities Fraud Investigation Into Nutex Health Inc. (NUTX) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

Nutex Health Inc. (NUTX) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

Securities Fraud Investigation Into Nutex Health Inc. (NUTX) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm

Legal

Nutex Health Inc. Investors: Company Investigated by the Portnoy Law Firm

INVESTIGATION ALERT: Edelson Lechtzin LLP Announces an Investigation of Nutex Health Inc. (NASDAQ: NUTX) and Encourages Investors with Substantial Losses or Witnesses with Relevant Information to Contact the Firm

Nutex Health (NUTX) Shares Fall Amid Critical Blue Orca Report -- Hagens Berman

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nutex Health Inc. - NUTX

NUTX

Agilon Health

AirSculpt Technologies, Inc. - Common Stock

AirSculpt Technologies

AMN Healthcare Services

Astrana Health

Aveanna Healthcare Holdings Inc. - Common Stock

Aveanna Healthcare Hldgs

BrightSpring Health Services, Inc. - Tangible Equity Unit

BrightSpring Health

Concord Medical Services Holdings Limited American Depositary Shares (Each represents thirty (30) Class A ordinary shares)

Comments

Nutex Health

Nutex Health (NUTX) Options

No option chain data available. Please try again later

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL